

# Gaurab Chakrabarti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11107380/publications.pdf>

Version: 2024-02-01

11  
papers

516  
citations

933447  
10  
h-index

1281871  
11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

1108  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hydrogen peroxide inhibition of bicupin oxalate oxidase. PLoS ONE, 2017, 12, e0177164.	2.5	3
2	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. Cancer Cell, 2016, 30, 940-952.	16.8	104
3	NQO1-Mediated Tumor-Selective Lethality and Radiosensitization for Head and Neck Cancer. Molecular Cancer Therapeutics, 2016, 15, 1757-1767.	4.1	46
4	Depleting Tumor-NQO1 Potentiates Anoikis and Inhibits Growth of NSCLC. Molecular Cancer Research, 2016, 14, 14-25.	3.4	50
5	Using DNA devices to track anticancer drug activity. Biosensors and Bioelectronics, 2016, 80, 647-653.	10.1	10
6	Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, $\hat{\imath}^2$ -lapachone. Scientific Reports, 2015, 5, 17066.	3.3	50
7	Mutant KRAS associated malic enzyme 1 expression is a predictive marker for radiation therapy response in non-small cell lung cancer. Radiation Oncology, 2015, 10, 145.	2.7	47
8	Expanding antitumor therapeutic windows by targeting cancer-specific nicotinamide adenine dinucleotide phosphate-biogenesis pathways. Clinical Pharmacology: Advances and Applications, 2015, 7, 57.	1.2	12
9	Targeting glutamine metabolism sensitizes pancreatic cancer to PARP-driven metabolic catastrophe induced by $\hat{\imath}^2$ -lapachone. Cancer & Metabolism, 2015, 3, 12.	5.0	104
10	Tumor-Selective, Futile Redox Cycle-Induced Bystander Effects Elicited by NQO1 Bioactivatable Radiosensitizing Drugs in Triple-Negative Breast Cancers. Antioxidants and Redox Signaling, 2014, 21, 237-250.	5.4	37
11	What is evaluation of hematuria by primary care physicians? Use of electronic medical records to assess practice patterns with intermediate follow-up. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 128-134.	1.6	53